Study wrapper · #614
Hexarelin treatment in male ghrelin knockout mice after myocardial infarction.
Editor's note
Using ghrelin-knockout mice after myocardial infarction, researchers compared hexarelin and equimolar ghrelin against vehicle. Both peptides sharply reduced two-week mortality (hexarelin 6.7%, ghrelin 14.3%, vehicle 50%) and improved cardiac output and systolic and diastolic function, with hexarelin outperforming ghrelin on several indices. Both suppressed sympathetic nervous activity. The design cleverly tests whether hexarelin can substitute for absent endogenous ghrelin, and it does. Still, this is a single acute rodent model with small numbers, and the mortality figures come from modest group sizes. These are preclinical findings; human data are needed before any clinical conclusions can be drawn, and the cross-species leap to patients remains large.
Plain-language abstract
Researchers used mice genetically lacking the natural hormone ghrelin to test whether hexarelin, a synthetic peptide, could take its place after a heart attack. After a coronary artery was tied off, mice received hexarelin, ghrelin, or an inactive vehicle for two weeks. Far fewer treated mice died (about 7% with hexarelin and 14% with ghrelin, versus 50% with vehicle), and both peptides improved heart pumping and relaxation, with hexarelin doing somewhat better on several measures. Both calmed the 'fight-or-flight' branch of the nervous system. The study suggests hexarelin can compensate for missing ghrelin in this model. These are preclinical findings in mice with small group sizes; human studies would be needed before any clinical conclusions.